Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 2/20 | 0.54 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.54 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.54 |
| ▸ | ITGAV | P06756 | 1/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.54 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.54 |
| ▸ | ITGAL | P20701 | 1/20 | 0.54 |
| ▸ | NR2F2 | P24468 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.42 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.42 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12318414 | 0.80 | NR2F2 (0.44) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL12270577 | 0.80 | NR2F2 (0.47) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL2723878 | 0.78 | ITGB1 (0.50) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL4532111 | 0.78 | ITGB1 (0.50) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL10248614 | 0.78 | — | — | |
| SCHEMBL6603075 | 0.75 | SLC6A1 (0.50) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL4979634 | 0.74 | ITGB1 (0.50) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL24107983 | 0.74 | ITGB1 (0.55) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL28109850 | 0.73 | CRBN (0.46) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL9060863 | 0.73 | ITGB1 (0.43) | ITGB1ITGA5ITGB3ITGB2ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122069877-A | Perovskite solar cell | 中茂绿能科技(西安)有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122069877-A | Perovskite solar cell | 中茂绿能科技(西安)有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20240016946-A1 | DRUG-LOADED MACROMOLECULE AND PREPARATION METHOD THEREFOR | SHANGHAI SHENGDI PHARMACEUTICAL CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-26 | — | — | US | disclosed |
| EP-3018123-B1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-10 | — | — | EP | disclosed |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| WO-2021252849-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252859-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210277030-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-09 | — | — | US | disclosed |
| EP-3018123-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-9023146-B2 | Oxidizing agents on pigments | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2015-05-05 | — | — | US | disclosed |
| US-8853215-B2 | Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20140083323-A1 | OXIDIZING AGENTS ON PIGMENTS | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140066420-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| US-8586571-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2419413-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| WO-2010119992-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | ITGB1 4576/4885ITGA5 2982/4885ITGB3 4310/4885 |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, NPC1L1 | ITGB1 663/4885ITGA5 2260/4885ITGB3 2019/4885 |
| US-20140066420-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RAVER1 | ITGB1 4471/4885ITGA5 3828/4885ITGB3 4165/4885 |
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | ITGB1 1660/4885ITGA5 2539/4885ITGB3 2988/4885 |
| US-20210277030-A1 | AMIDE COMPOUND | RORB, RORC, RORA | ITGB1 3155/4885ITGA5 2936/4885ITGB3 3823/4885 |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | RORB, RORC, RORA | ITGB1 3717/4885ITGA5 3818/4885ITGB3 4075/4885 |
| US-20240016946-A1 | DRUG-LOADED MACROMOLECULE AND PREPARATION METHOD THEREFOR | MRPL38, MRPS27, MRPS18A | ITGB1 782/4885ITGA5 1191/4885ITGB3 2237/4885 |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RAVER1 | ITGB1 4471/4885ITGA5 3828/4885ITGB3 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.